The incidence of papillary thyroid carcinoma(PTC)has exponentially increased in recent years.Papillary thyroid microcarcinoma(PTMC)accounts for the majority of the reported cases of PTC.The debates and crucial issues ...The incidence of papillary thyroid carcinoma(PTC)has exponentially increased in recent years.Papillary thyroid microcarcinoma(PTMC)accounts for the majority of the reported cases of PTC.The debates and crucial issues in PTMC management have received researchers'attention.To further improve the clinical management of PTMC in China,展开更多
In recent years, the clinical incidence of thyroid cancer has been increasing year by year, and its risk assessment and clinical management methods have also been accordingly modified and constantly improved. There ar...In recent years, the clinical incidence of thyroid cancer has been increasing year by year, and its risk assessment and clinical management methods have also been accordingly modified and constantly improved. There are great differences between the clinical diagnostic and therapeutic modes and disease management of thyroid cancer employed by various medical institutions in China, particularly with regard to the clinical application of serum marker of thyroid cancer. To this end, the China Anti-Cancer Association Thyroid Cancer Specialized Committee Chinese Association of Thyroid Oncology organized this compilation of ExpertConsensus on Clinical Application of Serum Marker of Thyroid Cancer to help and impel relevant clinical institutions and professionals to standardize clinical diagnosis, treatment, and long-term management of thyroid cancer, and to properly utilize the serum marker for scientific auxiliary clinical diagnosis and assessment of thyroid cancer before and after operation.展开更多
Cholestatic liver disease (CLD) is a common problem in clinical practice with the main manifestation being cholestasis.Recently,there has been a steady increase in knowledge associated with the diagnosis and treatment...Cholestatic liver disease (CLD) is a common problem in clinical practice with the main manifestation being cholestasis.Recently,there has been a steady increase in knowledge associated with the diagnosis and treatment of CLD.Therefore,the experts in China were organized by the editorial board of Chinese Journal of Experimental and Clinical Infectious Diseases (Electronic Edition),Chinese Journal of Liver Diseases (Electronic Edition) and Infection International (Electronic Edition) to collect and analyze relevant research,ultimately resulting in the development of this work (Chinese Expert consensus for the diagnosis and treatment of CLDs,also abbreviated as consensus).展开更多
Although many population pharmacokinetics（PPK） researches have been conducted on chemical drugs,few have been in the field of Chinese medicine（CM）.Each ingredient in CMs possesses different pharmacokinetic charact...Although many population pharmacokinetics（PPK） researches have been conducted on chemical drugs,few have been in the field of Chinese medicine（CM）.Each ingredient in CMs possesses different pharmacokinetic characteristics,therefore,it is important to develop methods of PPK studies on them to identify the differences in CM drug safety and efficacy among the population subgroups and to conduct quantitative studies on the determinants of CM drug concentrations.To develop an expert consensus on study design and implementation for PPK of CM,in August 2013,6 experts in the field of PPK,CMs pharmacology,and statistics discussed problems on the PPK research protocol of CMs,and a consensus was reached.The medicines with toxicity and narrow therapeutic windows and with wide range of target population or with frequent adverse reactions were selected.The compositions with definite therapeutic effects were selected as indices,and specific time points and sample sizes were designed according to standard PPK design methods.Target components were tested through various chromatography methods.Total quantity statistical moment analysis was used to estimate PPK parameters of each component and PPK models reflecting the trend of CMs（which assists in reasonable adjustments on clinical dosage）.This consensus specifies the study design and implementation process of PPK.It provides guidance for the following：post-marketing clinical studies,in vivo investigations related to the metabolism in different populations,and development and clinical adjustment of dosages of CMs.展开更多
Although the number of hepatocellular carcinoma(HCC)patients is decreasing due to the development of hepatic anti-virus therapy,it remains a leading cause of cancer-related death worldwide.The recent development of sy...Although the number of hepatocellular carcinoma(HCC)patients is decreasing due to the development of hepatic anti-virus therapy,it remains a leading cause of cancer-related death worldwide.The recent development of systemic or locoregional therapy for advanced or unresectable HCC has enabled advanced HCC to be downstaged,and reports of conversion therapy have increased;however,many clinical and scientific subjects rely on the therapeutic strategies of advanced HCC.There is a need to assess the evidence and develop clinical guidelines for conversion therapy for HCC;therefore,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition),consisting of 16 statements,has been developed for clinical practice(1).This consensus addresses treatment strategies for both technically and oncologically unresectable HCCs.We applaud Chinese establishment of this comprehensive and cutting-edge consensus on the treatment of advanced HCC.展开更多
文摘The incidence of papillary thyroid carcinoma(PTC)has exponentially increased in recent years.Papillary thyroid microcarcinoma(PTMC)accounts for the majority of the reported cases of PTC.The debates and crucial issues in PTMC management have received researchers'attention.To further improve the clinical management of PTMC in China,
文摘In recent years, the clinical incidence of thyroid cancer has been increasing year by year, and its risk assessment and clinical management methods have also been accordingly modified and constantly improved. There are great differences between the clinical diagnostic and therapeutic modes and disease management of thyroid cancer employed by various medical institutions in China, particularly with regard to the clinical application of serum marker of thyroid cancer. To this end, the China Anti-Cancer Association Thyroid Cancer Specialized Committee Chinese Association of Thyroid Oncology organized this compilation of ExpertConsensus on Clinical Application of Serum Marker of Thyroid Cancer to help and impel relevant clinical institutions and professionals to standardize clinical diagnosis, treatment, and long-term management of thyroid cancer, and to properly utilize the serum marker for scientific auxiliary clinical diagnosis and assessment of thyroid cancer before and after operation.
文摘Cholestatic liver disease (CLD) is a common problem in clinical practice with the main manifestation being cholestasis.Recently,there has been a steady increase in knowledge associated with the diagnosis and treatment of CLD.Therefore,the experts in China were organized by the editorial board of Chinese Journal of Experimental and Clinical Infectious Diseases (Electronic Edition),Chinese Journal of Liver Diseases (Electronic Edition) and Infection International (Electronic Edition) to collect and analyze relevant research,ultimately resulting in the development of this work (Chinese Expert consensus for the diagnosis and treatment of CLDs,also abbreviated as consensus).
基金Supported by the Significant Drug Research and Development in Important State Science and Technology Specific and Key Technique Research(No.2009ZX09502-030)Visiting Fellow Joint Innovation Research Project of the China Academy of Chinese Medicial Sciences(No.ZZ070834)the Specialty Committee of Evaluation of Postmarketing Chinese Medicines of World Federation of Chinese Medicine Societies
文摘Although many population pharmacokinetics（PPK） researches have been conducted on chemical drugs,few have been in the field of Chinese medicine（CM）.Each ingredient in CMs possesses different pharmacokinetic characteristics,therefore,it is important to develop methods of PPK studies on them to identify the differences in CM drug safety and efficacy among the population subgroups and to conduct quantitative studies on the determinants of CM drug concentrations.To develop an expert consensus on study design and implementation for PPK of CM,in August 2013,6 experts in the field of PPK,CMs pharmacology,and statistics discussed problems on the PPK research protocol of CMs,and a consensus was reached.The medicines with toxicity and narrow therapeutic windows and with wide range of target population or with frequent adverse reactions were selected.The compositions with definite therapeutic effects were selected as indices,and specific time points and sample sizes were designed according to standard PPK design methods.Target components were tested through various chromatography methods.Total quantity statistical moment analysis was used to estimate PPK parameters of each component and PPK models reflecting the trend of CMs（which assists in reasonable adjustments on clinical dosage）.This consensus specifies the study design and implementation process of PPK.It provides guidance for the following：post-marketing clinical studies,in vivo investigations related to the metabolism in different populations,and development and clinical adjustment of dosages of CMs.
文摘Although the number of hepatocellular carcinoma(HCC)patients is decreasing due to the development of hepatic anti-virus therapy,it remains a leading cause of cancer-related death worldwide.The recent development of systemic or locoregional therapy for advanced or unresectable HCC has enabled advanced HCC to be downstaged,and reports of conversion therapy have increased;however,many clinical and scientific subjects rely on the therapeutic strategies of advanced HCC.There is a need to assess the evidence and develop clinical guidelines for conversion therapy for HCC;therefore,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition),consisting of 16 statements,has been developed for clinical practice(1).This consensus addresses treatment strategies for both technically and oncologically unresectable HCCs.We applaud Chinese establishment of this comprehensive and cutting-edge consensus on the treatment of advanced HCC.
